Peri-operative Chemotherapy With ECX or XP in the Treatment of Advanced Gastric Cancer

University of Chinese Academy Sciences

Status and phase: Unknown; Phase 2

Conditions: Gastric Cancer

Treatments: Drug: Peri-operative chemotherapy of ECX; Drug: Peri-operative chemotherapy of XP

Study type: Interventional

Funder types: Other

Identifiers

NCT01558947

PC-AGC-01

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and the effect of perioperative chemotherapy in the treatment of advanced gastric cancer.

Full description

To evaluate the security and the relapse-free survival time/rate(1,2,3 yrs) of perioperative chemotherapy with ECX (epirubicin + cisplatin + capecitabine) and XP (capecitabine + cisplatin）in advanced gastric cancer

Enrollment: 2 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female aged 18 to 70 years old.
• The preoperative evaluation: gastric cancer patients, ≥ T2 or N +; or staging II, IIIA, IIIB.
• Karnofsky score ≥ 70, life expectancy > 6 months.
• Endoscopic biopsy diagnosis of gastric cancer, excluding non-Hodgkin's lymphoma, leiomyosarcoma and other mesenchymal tumors.
• the blood and biochemical indicators of the subjects must meet the following criteria: Hb ≥ 9 g / dl; WBC ≥ 4,000 / mm3, ≤ 12000 / mm3; PLT ≥ 100,000/mm3; GOT, GPT within twice the institutional limit,serum total bilirubin < 1.5 times the upper limit of normal, serum creatinine< 1.25 times the upper limit of normal and creatinine clearance rate ≥ 60ml/min, LVEF ≥ 60%.
• have not received prior chemotherapy, radiotherapy and biological therapy.
• signed informed consent.
• must accept the standard D2 or D2 + radical gastrectomy.
• with good compliance.

Exclusion criteria

• pregnancy, breast-feeding women.
• allergy with chemotherapy drugs or metabolic disorder.
• the history of organ transplants (including bone marrow transplantation and autologous peripheral stem cell transplantation).
• had long received systemic steroid treatment (Note: short-term users of withdrawal > 2 weeks can be selected.)
• The existence of the peripheral nervous system disorders or significant neurological disorders and a history of central nervous system disorders.
• patients with severe infection requires treatment.
• patients associated with dysphagia, active peptic ulcer, incompleteness intestinal obstruction, active gastrointestinal bleeding, perforation.
• severe liver disease (such as cirrhosis), kidney disease, respiratory disease or uncontrollable diabetes.
• with other malignancies which were not cured.
• EKG abnormalities or heart disease with apparent clinical symptoms, including congestive heart failure, coronary heart disease with symptoms, uncontrollable arrhythmia, hypertension, and heart attack within 12 months or III or IV grade myocardial infarction. Coronary heart disease with symptoms, uncontrollable arrhythmia, hypertension, and heart attack within 12 months or III or IV grade myocardial infarction.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

2 participants in 2 patient groups

chemotherapy with ECX

Experimental group

Description:

chemotherapy with ECX

Treatment:

Drug: Peri-operative chemotherapy of ECX

chemotherapy with XP

Experimental group

Description:

chemotherapy with XP

Treatment:

Drug: Peri-operative chemotherapy of XP